Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. FBRX
FBRX logo

FBRX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Forte Biosciences Inc (FBRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
17.850
1 Day change
1.48%
52 Week Range
35.800
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Forte Biosciences Inc (FBRX) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of significant positive trading trends, no recent news catalysts, and neutral technical indicators suggest limited immediate upside potential. Additionally, no proprietary trading signals (AI Stock Picker or SwingMax) are present to support a buy decision.

Technical Analysis

The MACD histogram is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral at 51.836, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 17.08, with resistance at 18.249 and support at 15.911, suggesting limited immediate upside.

Options Data

Bullish
Open Interest Put-Call Ratio
Neutral
Option Volume Put-Call Ratio

The open interest put-call ratio indicates a slightly bearish sentiment, while the option volume put-call ratio is neutral. Implied volatility is high at 187.13, suggesting elevated uncertainty.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
3

Positive Catalysts

  • The MACD is positively expanding, and there is a 70% chance of a 10.78% increase in the next month based on candlestick pattern analysis.

Neutral/Negative Catalysts

  • No recent news, no significant hedge fund or insider trading activity, and no recent congress trading data. The moving averages are bearish, and the stock lacks strong momentum.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for FBRX.

Wall Street analysts forecast FBRX stock price to rise
2 Analyst Rating
Wall Street analysts forecast FBRX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.590
sliders
Low
65
Averages
65
High
65
Current: 17.590
sliders
Low
65
Averages
65
High
65
Evercore ISI
Outperform
initiated
$65
AI Analysis
2025-11-25
Reason
Evercore ISI
Price Target
$65
AI Analysis
2025-11-25
initiated
Outperform
Reason
Evercore ISI initiated coverage of Forte Biosciences with an Outperform rating and $65 price target. There has been a notable re-rating in development-stage microcap companies, especially those with important proof of concept data in 2025 and 2026, notes the analyst. While arguing that Forte "falls squarely in this bucket," the firm notes shares have been slow to get the same bid until the last two weeks, adding that it thinks the setup is "super attractive into a catalyst-rich 2026."
Guggenheim
NULL -> Buy
initiated
$75
2025-08-18
Reason
Guggenheim
Price Target
$75
2025-08-18
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for FBRX
Unlock Now

People Also Watch